BE836835A - Nouveaux acides amino cycliques - Google Patents

Nouveaux acides amino cycliques

Info

Publication number
BE836835A
BE836835A BE6045299A BE6045299A BE836835A BE 836835 A BE836835 A BE 836835A BE 6045299 A BE6045299 A BE 6045299A BE 6045299 A BE6045299 A BE 6045299A BE 836835 A BE836835 A BE 836835A
Authority
BE
Belgium
Prior art keywords
aminocyclic
acids
new
new aminocyclic
aminocyclic acids
Prior art date
Application number
BE6045299A
Other languages
English (en)
French (fr)
Inventor
G Satzinger
J Hartenstein
M Herrmann
W Heldt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5934284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE836835(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BE836835A publication Critical patent/BE836835A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE6045299A 1974-12-21 1975-12-18 Nouveaux acides amino cycliques BE836835A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2460891A DE2460891C2 (de) 1974-12-21 1974-12-21 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
BE836835A true BE836835A (fr) 1976-06-18

Family

ID=5934284

Family Applications (1)

Application Number Title Priority Date Filing Date
BE6045299A BE836835A (fr) 1974-12-21 1975-12-18 Nouveaux acides amino cycliques

Country Status (16)

Country Link
US (1) US4024175A (de)
JP (1) JPS5324064B2 (de)
AT (1) AT340892B (de)
BE (1) BE836835A (de)
CA (1) CA1052811A (de)
CH (3) CH612665A5 (de)
DE (1) DE2460891C2 (de)
DK (1) DK147706C (de)
ES (1) ES443723A1 (de)
FI (1) FI62282C (de)
FR (1) FR2294697A1 (de)
GB (1) GB1465229A (de)
IE (1) IE42382B1 (de)
LU (1) LU74058A1 (de)
NL (1) NL181006C (de)
SE (1) SE423385B (de)

Families Citing this family (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2611690A1 (de) * 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
JPS5776189U (de) * 1980-10-28 1982-05-11
JPS6152583U (de) * 1984-09-11 1986-04-09
JPS61139881U (de) * 1985-02-21 1986-08-29
US4876279A (en) * 1986-05-05 1989-10-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
YU162789A (en) * 1988-09-01 1990-12-31 Lonza Ag 2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones
US5319135A (en) * 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
US5132451A (en) * 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
AU633612B2 (en) * 1989-08-25 1993-02-04 Warner-Lambert Company Improved process for cyclic amino acid anticonvulsant compounds
DE3928182A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5136091A (en) * 1989-11-16 1992-08-04 Lonza Ltd. Process for the production of 1-(aminomethyl) cyclohexane acetic acid
US5157138A (en) * 1989-11-16 1992-10-20 Pfizer, Inc. Glutaric acid derivatives and preparation thereof
US5149870A (en) * 1989-11-16 1992-09-22 Lonza Ltd. Process for the production of 1-(aminomethyl)cyclohexane acetic acid
GB8925933D0 (en) * 1989-11-16 1990-01-04 Pfizer Ltd Glutaric acid derivatives and preparation thereof
US5260467A (en) * 1989-11-16 1993-11-09 Pfizer Inc. Glutaric acid derivatives and preparation thereof
FI905584L (fi) * 1989-11-16 1991-05-17 Lonza Ag Foerfarande foer framstaellning av 1-(aminometyl)cyklohexanaettikssyra.
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
EP0888325B1 (de) * 1996-02-07 2002-05-29 Warner-Lambert Company Zyklischaminosäure als pharmazeutische mittel
WO1997033859A1 (en) * 1996-03-14 1997-09-18 Warner-Lambert Company Novel bridged cyclic amino acids as pharmaceutical agents
HU224720B1 (en) * 1996-03-14 2006-01-30 Warner Lambert Co Novel substituted cyclic amino acid derivatives use as pharmaceutical agents
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
ATE361909T1 (de) * 1996-10-23 2007-06-15 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
US6255526B1 (en) 1996-12-24 2001-07-03 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
AU9019198A (en) 1997-08-19 1999-03-08 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
WO1999012537A1 (en) * 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
WO1999018063A2 (en) 1997-10-07 1999-04-15 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
ATE323067T1 (de) * 1997-10-27 2006-04-15 Warner Lambert Co Zyklische aminosäuren und deren derivate als arzneimittel
US6984659B2 (en) * 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
CN1131855C (zh) * 1997-12-16 2003-12-24 沃尼尔·朗伯公司 1－取代－1－氨基甲基－环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
SI1045839T1 (en) 1997-12-16 2004-06-30 Warner-Lambert Company Llc Novel amines as pharmaceutical agents
CA2304967C (en) 1997-12-16 2005-06-14 Warner-Lambert Company 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
CA2309354A1 (en) * 1998-01-23 1999-07-29 Leslie Magnus-Miller Gabapentin and its derivatives for the treatment of muscular and skeletal pain
EP0974351A3 (de) * 1998-04-24 2000-12-13 Jouveinal Arzneimittel zur Vorbeugung und Behandlung von Magendarmschäden
ID26395A (id) * 1998-05-15 2000-12-21 Warner Lambert Comapny Turunan asam gamma-aminobutirat yang mengandung komposisi padat dan proses pembuatannya
ATE271864T1 (de) 1998-05-15 2004-08-15 Warner Lambert Co Aminosäure-stabilisierte gabapentin und pregabalin zubereitungen und verfahren zu ihrer herstellung
ES2137137B1 (es) * 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
WO1999061424A1 (en) 1998-05-26 1999-12-02 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
ITMI981535A1 (it) * 1998-07-03 2000-01-03 Zambon Spa Processo per la preparazione di gabapentina
US20030045500A1 (en) * 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
FR2781793B1 (fr) 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
HU225502B1 (en) * 1998-12-29 2007-01-29 Richter Gedeon Vegyeszet Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
IT1311984B1 (it) 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
DE60022333T2 (de) * 1999-04-09 2006-07-06 Euro-Celtique S.A. Natrium kanalblocker zusammensetzungen und deren verwendung
US6710190B1 (en) * 1999-05-28 2004-03-23 Warner-Lambert Company 3-heteroarylalkyl substituted gaba analogs
PT1185524E (pt) * 1999-05-28 2005-04-29 Warner Lambert Co Analogos de gaba substituidos por 3-heteroarilalquilo
ES2317839T3 (es) * 1999-06-10 2009-05-01 Warner-Lambert Company Llc Acidos 3-propil gamma-aminobutiricos monosustituidos.
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
EP1384473A1 (de) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stabiles Gabapentin das mehr als 20 ppm Chlor enthält
PL363155A1 (en) * 2000-06-16 2004-11-15 Teva Pharmaceutical Industries, Ltd. Stable gabapentin having ph within a controlled range
DE60101476T2 (de) 2000-06-16 2004-05-27 Teva Pharmaceutical Industries Ltd. Stabiles gabapentin, das mehr als 20 ppm chlor enthält
IL152770A0 (en) * 2000-06-26 2003-06-24 Warner Lambert Co Gabapentin analogues for sleep disorders
GB2364049A (en) * 2000-06-28 2002-01-16 Warner Lambert Co Cyclic ketones and their use in the synthesis of amino acids
MXPA03002090A (es) * 2000-09-14 2003-06-19 Gruenenthal Gmbh °-tio-aminoacidos.
EP1361847A2 (de) * 2000-10-06 2003-11-19 Xenoport, Inc. Gallensäurekonjugate zur bereitstellung anhaltender systemischer arneimittelkonzentrationen
WO2002028881A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6620829B2 (en) * 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
IT1319234B1 (it) * 2000-10-23 2003-09-26 Zambon Spa Processo di preparazione di gabapentina.
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
DE01981893T1 (de) 2000-11-02 2004-05-19 Teva Pharmaceutical Industries Ltd. Verbessertes verfahren zur herstellung eines gabapentin-zwischenprodukts
EP1337272A2 (de) * 2000-11-30 2003-08-27 Pfizer Products Inc. Kombination von gaba agonisten und aldose reductase inhibitoren
BR0115783A (pt) * 2000-11-30 2003-09-16 Pfizer Prod Inc Combinação de agonistas de gaba e inibidores de sorbitol desidrogenase
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
US20040063994A1 (en) * 2001-03-16 2004-04-01 Paolo Rossi Process for the preparation of cyclic amino acids
ITMI20011132A1 (it) 2001-05-29 2002-11-29 Procos Spa Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7420002B2 (en) * 2001-06-11 2008-09-02 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
ATE540678T1 (de) * 2001-06-11 2012-01-15 Xenoport Inc Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
IL144066A0 (en) * 2001-06-28 2002-04-21 Bromine Compounds Ltd Process for the preparation of 1,1-cyclohexane diacetic monoamide
ITMI20011772A1 (it) 2001-08-10 2003-02-10 A M S A Anonima Materie Sint E Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide)
IL160523A0 (en) 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
US6800782B2 (en) * 2001-10-09 2004-10-05 Warner-Lambert Co. Anhydrous crystalline forms of gabapentin
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
AU2003201716B2 (en) * 2002-01-31 2008-04-17 Warner-Lambert Company Llc Alpha 2 delta ligands to treat tinnitus
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2003077902A1 (en) * 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
AU2003222033A1 (en) * 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
CA2478471A1 (en) * 2002-04-16 2003-10-30 Taro Pharmaceutical Industries Ltd. Process for preparing gabapentin
WO2003094842A2 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
WO2003099338A2 (en) * 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2003239752A1 (en) * 2002-06-27 2004-01-19 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
CA2395931A1 (en) * 2002-08-07 2004-02-07 Bernard Charles Sherman Solid compositions comprising gabapentin having improved stability
US7053122B2 (en) * 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092591A1 (en) * 2002-08-15 2004-05-13 Blakemore David Clive Therapeutic use of fused bicyclic or tricyclic amino acids
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US20040092498A1 (en) * 2002-08-16 2004-05-13 David Blakemore Substituted glycine derivatives for use as medicaments
ITMI20022071A1 (it) * 2002-10-01 2004-04-02 Erregierre Spa Processo di sintesi dell'acido 1-(aminometil)cicloesanacetico cloridato.
US7659305B2 (en) * 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
EP1727784B1 (de) * 2002-11-18 2008-12-24 Nicholas Piramal India Limited Verbessertes verfahren zur herstellung von gabapentin
WO2004046108A1 (en) * 2002-11-20 2004-06-03 Hikal Ltd. An improved process for the preparation of gabalactam
WO2004052360A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
BR0317253A (pt) * 2002-12-13 2005-11-01 Warner Lambert Co Derivados pregabalina para o tratamento da fibromialgia e outras patologias
PL377286A1 (pl) * 2002-12-13 2006-01-23 Warner-Lambert Company Llc Analogi gabapentyny do włókniako-mięśniakowych i innych pokrewnych zaburzeń
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
MXPA05006209A (es) * 2002-12-13 2005-08-19 Warner Lambert Co Pregabalina y sus derivados para el tratamiento de fibromialgia y otros trastornos relacionados.
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
GB0301143D0 (en) * 2003-01-17 2003-02-19 Amedis Pharm Ltd Compounds and their use
CN1764634A (zh) * 2003-01-22 2006-04-26 沃尼尔·朗伯有限责任公司 环丙基β－氨基酸衍生物
WO2004078734A1 (en) * 2003-03-07 2004-09-16 Warner-Lambert Company Llc TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES
WO2004093866A1 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Process for preparing phenolic acid salts of gabapentin
EP1622603A4 (de) * 2003-03-25 2010-03-24 Kiel Lab Inc Phenolsäuresalze von gabapentin in festen dosierformen und anwendungsverfahren
WO2004093867A2 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use
JP2006522146A (ja) * 2003-03-31 2006-09-28 ゼノポート，インコーポレイティド Ｇａｂａ類似体のプロドラッグを使用するのぼせの治療または予防
WO2004091278A2 (en) * 2003-04-11 2004-10-28 Transform Pharmaceuticals, Inc. Gabapentin compositions
ITMI20030825A1 (it) * 2003-04-18 2004-10-19 Farchemia Srl Procedimento per la preparazione di gabapentin esente da
WO2004093780A2 (en) * 2003-04-21 2004-11-04 Matrix Laboratories Ltd Process for the preparation of gabapentin form-ii
WO2004100992A2 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
WO2004111256A1 (en) * 2003-06-19 2004-12-23 Pfizer Products Inc. Biocatalytic preparation of 1-cyanocyclohexaneacetic acid
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
KR20060119971A (ko) * 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
NZ545494A (en) 2003-09-12 2009-10-30 Pfizer Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
AU2004271796A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Combination comprising an alpha-2-delta ligand and an SSRI and/or SNRI for treatment of depression and anxiety disorders
AU2004274002B2 (en) * 2003-09-17 2011-04-28 Arbor Pharmaceuticals, Llc Treating or preventing restless legs syndrome using prodrugs of GABA analogs
PT1677767E (pt) * 2003-10-14 2011-10-13 Xenoport Inc Forma cristalina de análogo de ácido gama-aminobutírico
ITMI20032165A1 (it) * 2003-11-11 2005-05-12 Zambon Spa Processo di preparazione di gabapentina
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2005082372A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
CA2570255A1 (en) * 2004-03-17 2005-09-22 Hikal Limited 4-t-butylgabapentin and its synthesis
ITMI20040579A1 (it) * 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
BRPI0511941A (pt) * 2004-06-09 2008-01-22 Pfizer uso de (s, s)-reboxetina ou reboxetina racêmica
GB0416228D0 (en) * 2004-07-20 2004-08-25 Sandoz Ind Products S A Process for the preparation of gabapentin
GB0419849D0 (en) * 2004-09-07 2004-10-13 Pfizer Ltd Pharmaceutical combination
ATE471147T1 (de) * 2004-09-10 2010-07-15 Newron Pharm Spa Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
CA2584338C (en) 2004-11-04 2013-08-06 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
EP1928437A2 (de) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese mittels muscarinrezeptormodulation
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
WO2007035945A1 (en) * 2005-09-23 2007-03-29 Janssen Pharmaceutica, N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
PL1937259T3 (pl) * 2005-09-23 2012-04-30 Janssen Pharmaceutica Nv Heksahydrocykloheptapirazolowe modulatory receptora kanabinoidowego
PT1931335E (pt) * 2005-09-23 2010-03-23 Janssen Pharmaceutica Nv Moduladores canabinóides de hexa-hidrociclooctil-pirazole
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US7526911B2 (en) * 2006-02-03 2009-05-05 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
EP1820502A1 (de) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Wirkstoffzusammensetzungen enthaltend Azolycarbinolderivate
US7795294B2 (en) * 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
CN101420947A (zh) * 2006-03-06 2009-04-29 辉瑞产品公司 用于非恢复性睡眠的α-2-δ配体
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
US8012957B2 (en) * 2006-03-27 2011-09-06 Janssen Pharmaceutica Nv Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7442834B2 (en) * 2006-06-12 2008-10-28 Zhejiang Chiral Medicine Chemicals Co., Ltd. Process suitable for industrial scale production of gabapentin
EP2038249B1 (de) * 2006-06-30 2013-09-11 ZaCh System S.p.A. Verfahren zur herstellung von gabapentin
EP2068872A1 (de) 2006-09-08 2009-06-17 Braincells, Inc. Kombinationen mit einem 4-acylaminopyridin-derivat
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008073257A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
CA2673545A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids
CA2679741A1 (en) * 2007-03-15 2008-09-18 Sun Pharma Advanced Research Company Ltd. Novel prodrugs
WO2008157408A2 (en) * 2007-06-15 2008-12-24 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090062392A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched gabapentin
US20090118365A1 (en) * 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
CA2706575C (en) * 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
EP2250148B1 (de) * 2008-01-25 2016-08-17 XenoPort, Inc. Kristalline form von kalziumsalzen von (3s)-aminomethyl-5-methylhexansäuren und anwendungsverfahren
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2116539A1 (de) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
CN105330603A (zh) 2008-10-08 2016-02-17 凯飞药业公司 Gaba偶联物及其使用方法
US9192681B2 (en) 2009-02-24 2015-11-24 Nektar Therapeutics Oligomer-amino acid conjugates
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
EP2509596B1 (de) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminosäure zur behandlung von augenerkrankungen
EP2353591A1 (de) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon
EP2368872A1 (de) 2010-03-25 2011-09-28 Serichim S.r.l. Verfahren zur Herstellung von Gabapentin
EP2388005A1 (de) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie
US20130078290A1 (en) 2010-06-01 2013-03-28 Rubicon Research Private Limited Gastroretentive Dosage Forms Of GABA Analogs
US8431739B2 (en) 2010-06-14 2013-04-30 Divi's Laboratories, Ltd. Process for the preparation of gabapentin
CA2805371C (en) 2010-07-30 2017-10-31 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
EP2415471A1 (de) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie
JP2013216580A (ja) * 2010-08-06 2013-10-24 Kyorin Pharmaceutical Co Ltd ビシクロ［２．２．２］オクチルアミン誘導体の製造方法
EP2524694A1 (de) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes
EP2530072A1 (de) 2011-06-03 2012-12-05 Lacer, S.A. Neue Verbindungen, deren Synthese und Verwendung bei der Schmerzbehandlung
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
ITMI20131757A1 (it) 2013-10-22 2015-04-23 Zach System Spa Processo di preparazione di gabapentina
DK3067430T3 (da) 2013-11-01 2020-09-21 Glytech Inc Fremgangsmåde til fremstilling af d-form-eller l-form-aminosyrederivat med en thiolgruppe
WO2015091505A1 (en) 2013-12-17 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Gabapentinoids and sigma receptor ligands combinations
TW201607538A (zh) 2013-12-17 2016-03-01 以斯提夫博士實驗室股份有限公司 血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物
EP2923694B1 (de) 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Orale flüssige pharmazeutische lösung von gabapentin
CN110072521B (zh) 2016-12-16 2022-11-29 爱杜西亚药品有限公司 包含t型钙通道阻断剂的药物组合
MX384760B (es) 2018-07-04 2025-03-14 Federico Amezcua Amezcua Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
US10399926B1 (en) 2018-08-01 2019-09-03 Divi's Laboratories Ltd. Process for the preparation of gabapentin
AU2018445164B2 (en) 2018-10-11 2025-05-29 Vifor (International) Ltd. Inositol phosphates for the treatment of ectopic calcification
CN114599397B (zh) 2019-10-25 2024-05-28 国立大学法人京都大学 Tau蛋白病的预防或治疗剂
EP4114379A4 (de) 2020-03-04 2024-01-17 Pleopharma, L.L.C. Verfahren und zusammensetzungen zur behandlung von störungen der cannabisverwendung und zur abschwächung des cannabinoidentzugs
EP4015494A1 (de) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Verfahren zur herstellung von löslichen salzen von inositolphosphaten
GB2625579A (en) 2022-12-21 2024-06-26 Novumgen Ltd An orally disintegrating tablet containing gabapentin or pharmaceutically acceptable salts thereof and the process of preparing the same

Also Published As

Publication number Publication date
ATA975075A (de) 1977-05-15
FR2294697A1 (fr) 1976-07-16
AU8774175A (en) 1977-06-23
DE2460891C2 (de) 1982-09-23
CA1052811A (en) 1979-04-17
FI753613A7 (de) 1976-06-22
NL181006C (nl) 1987-06-01
ES443723A1 (es) 1977-04-16
DK581475A (da) 1976-01-22
GB1465229A (en) 1977-02-23
DK147706B (da) 1984-11-19
NL181006B (nl) 1987-01-02
CH612665A5 (de) 1979-08-15
DK147706C (da) 1985-05-13
CH612666A5 (de) 1979-08-15
IE42382L (en) 1976-06-21
AT340892B (de) 1978-01-10
FR2294697B1 (de) 1978-07-28
IE42382B1 (en) 1980-07-30
US4024175A (en) 1977-05-17
JPS5324064B2 (de) 1978-07-18
JPS5188940A (de) 1976-08-04
SE7514442L (sv) 1976-06-22
LU74058A1 (de) 1976-07-20
SE423385B (sv) 1982-05-03
DE2460891A1 (de) 1976-07-01
FI62282C (fi) 1982-12-10
CH612664A5 (de) 1979-08-15
FI62282B (fi) 1982-08-31
NL7514900A (nl) 1976-06-23

Similar Documents

Publication Publication Date Title
BE836835A (fr) Nouveaux acides amino cycliques
BE820542A (fr) Nouveaux acides monoalkylamino-4-benzoiques
FR2273545A1 (fr) Nouveaux benzimidazols
FR2345430A1 (fr) Nouveaux acides acetohydroxamiques
BE820253A (fr) Esters d'amino acides
FR2274300A1 (fr) Antiarrhythmiques nouveaux
FR2275663A2 (fr) Pompe perfectionnee
BE820013A (fr) Acides carboxyphenyl-alkyphosphiniques
FR2306983A1 (fr) Nouveaux tetrazole-thiols
BE822933A (fr) Acides 7beta-acrylamidoceph-3-eme-4-carboxyliques
DK594575A (da) Peptid
BE827797A (fr) Nouveaux terpenophenols
BE829329R (fr) Nouveaux acides 7-acylamidocephalosporaniques thioles en position 3
BE833905A (fr) Nouveaux acides oxathiino- et dithiino- aminoacetiques et leur preparation
FR2284334A1 (fr) Nouveaux polypeptides
BE811821A (fr) Nouveaux acides perfluoroalkylalkylcarboxyliques
BE835637A (fr) Nouveaux n-phenylcarbamates
BE828980A (fr) Acides 2,3-polymethylene-5-sulfamoylbenzoiques
BE832229A (fr) Acides 19, 20-bis-nor-prostanoiques hypolipemiants
FR2281927A1 (fr) Nouveaux phenylcarbamates de 3-pyridylmethyle
BE825642A (fr) Nouveaux
BE828000A (fr) Acides 1,4-bis-formyl-cyclohexane-polycarboxyliques
BE832783A (fr) Amide
BE813693A (fr) Acides n-carboxyalkane-aminoalkane-phosphoniques et n-carboxyalkane aminoarylalkane-phosphoniques
BE834597A (fr) Nouveaux d-homosteroides

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: WARNER LAMBERT CY

Effective date: 19951218